5 Growth Stocks to Strengthen Your Portfolio in Q4 After a Fabulous Q3Zacks Investment Research • 10/10/25
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest ColonoscopiesBusiness Wire • 10/07/25
Exact Sciences (EXAS) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 10/01/25
Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-TermZacks Investment Research • 09/22/25
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® TestBusiness Wire • 09/22/25
Healthmine and Exact Sciences Partner to Combine At-Home CRC Screening with Health Plan Incentives to Boost Preventive CareBusiness Wire • 09/17/25
Exact Sciences Launches Cancerguard MCED Blood Test, Stock ClimbsZacks Investment Research • 09/12/25
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood TestBusiness Wire • 09/10/25
Exact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference (Transcript)Seeking Alpha • 09/09/25
Exact Sciences Corporation (EXAS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeeking Alpha • 09/03/25
Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®Business Wire • 08/22/25
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View UpZacks Investment Research • 08/12/25
Exact Sciences (EXAS) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 08/07/25
Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/06/25
Exact Sciences Tumbles On Plans To License Blood-Based Colon Cancer TestInvestors Business Daily • 08/06/25